Evidence map›Paper›PMID 41951573›Full record

Trial reportNature communications2026

L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial.

Frank A Giordano, Julian P Layer, Roberta Turiello, Lea L Friker, Oriol Mirallas, Barbara E F Pregler, Anna-Laura Potthoff, Thomas Zeyen, Johannes Weller, Elena Sperk and 21 more

Registry-linked trialAbstract readClinical Trial, Phase IIClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04121455 (Single-arm, Dose-escalation Phase 1/2 Study of Olaptesed Pegol), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04121455 phase1 / phase2active not recruitingnot on this map

Single-arm, Dose-escalation Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination With Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients With Unmethylated MGMT Promoter With a Multiple-arm Expansion Group

TypeinterventionalSponsorTME Pharma AGRan2019 to 2028Enrolled117ConditionsGlioblastomaArmsOlaptesed pegol, Radiotherapy, Bevacizumab, Pembrolizumab, Temozolomide (TMZ)
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Frank A Giordano *Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany. Frank.Giordano@umm.de.
Julian P Layer *Department of Radiation Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany.ORCID 0000-0001-7692-7775
Roberta TurielloInstitute of Experimental Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany.ORCID 0009-0000-6356-3917
Lea L FrikerInstitute of Experimental Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany.ORCID 0009-0005-5642-9062
Oriol MirallasMedical Oncology Department, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Barbara E F PreglerDepartment of Neurosurgery, University Hospital Bonn, University of Bonn, Bonn, Germany.
Anna-Laura PotthoffDepartment of Neurosurgery, University Hospital Bonn, University of Bonn, Bonn, Germany.
Thomas ZeyenDepartment of Neurooncology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Johannes WellerDepartment of Neurooncology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Elena SperkDepartment of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.ORCID 0000-0002-8771-8124
Katharina SahmDepartment of Neurology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Christoph OsterDepartment of Neurology, University Medicine Essen, University Duisburg-Essen, Essen, Germany.ORCID 0000-0002-0683-0430
Sied KebirDepartment of Neurology, University Medicine Essen, University Duisburg-Essen, Essen, Germany.
Peter HambschDepartment of Radiation Oncology, University of Leipzig Medical Center, University of Leipzig, Leipzig, Germany.
Niklas SchäferDepartment of Neurooncology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Sebastian KadzikInstitute of Experimental Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany.ORCID 0009-0005-3226-5219
Mirjam RenovanzDepartment of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Eberhard Karls University, Tübingen, Germany.
Torsten PietschInstitute of Neuropathology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Sotirios BisdasLysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London, United Kingdom.ORCID 0000-0001-9930-5549
Juan Manuel Sepúlveda-SánchezMedical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
Diego Gómez-PuertoMedical Oncology Department, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Maria VieitoMedical Oncology Department, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Michael PlattenDepartment of Neurology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.ORCID 0000-0002-4746-887X
Eleni GkikaDepartment of Radiation Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Oliver M GrauerDepartment of Neurology, University Hospital Münster, University of Münster, Münster, Germany.ORCID 0000-0003-4279-4497
Ghazaleh TabatabaiDepartment of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Eberhard Karls University, Tübingen, Germany.ORCID 0000-0002-3542-8782
Matthias SchneiderDepartment of Neurosurgery, University Hospital Bonn, University of Bonn, Bonn, Germany.ORCID 0000-0002-6025-7479
Martin GlasDepartment of Neurology, University Medicine Essen, University Duisburg-Essen, Essen, Germany.
Clemens SeidelDepartment of Radiation Oncology, University of Leipzig Medical Center, University of Leipzig, Leipzig, Germany.ORCID 0000-0001-8178-5089
Ulrich Herrlinger *Department of Neurooncology, University Hospital Bonn, University of Bonn, Bonn, Germany.ORCID 0000-0002-4011-9327
Michael Hölzel *Institute of Experimental Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany. michael.hoelzel@ukbonn.de.ORCID 0000-0003-4048-8824

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) EXC2151-390873048Deutsche Forschungsgemeinschaft (German Research Foundation) SFB1319/TP-B05
6 · The paper itself

Abstract

Rapid vascular recovery is a key feature preceding glioblastoma (GBM) recurrence after radiotherapy (RT). We performed spatial expression analyses, providing a rationale for dual inhibition of two non-redundant, spatially distinct acting factors, CXCL12 and VEGF. Subsequently, we expanded a multicentric phase 1/2 trial (NCT04121455), which initially combined RT and the CXCL12-neutralizing L-RNA-aptamer olaptesed pegol (NOX-A12) in patients with incompletely resected, newly-diagnosed GBM lacking MGMT promoter methylation. The primary endpoint was safety, secondary endpoints included maximum tolerable dose, recommended phase 2 dose, NOX-A12 plasma levels, topography of recurrence, tumor vascularization, neurologic assessment in neuro-oncology (NANO), quality of life, median progression-free survival (PFS), 6-months PFS and overall survival (OS). For the expansion arm, six patients were included that additionally received the VEGF-targeting antibody bevacizumab (BEV) to RT and NOX-A12. Combinatory treatment was well-tolerated and safe with no treatment-related deaths, resulting in abrogated tumor perfusion (rCBV, FTB

Indexed as

Aptamers, NucleotideBevacizumabBrain NeoplasmsChemokine CXCL12GlioblastomaAdultAgedFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalVascular Endothelial Growth Factor AAptamers, NucleotideBevacizumabChemokine CXCL12CXCL12 protein, humanNOX-A12Vascular Endothelial Growth Factor A

Identifiers

PMID41951573
PMCPMC13068908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.